Biogen

This study tests an experimental drug called BIIB122 in 650 people with early-stage Parkinson's disease. The goal is to see if the drug can slow down the worsening of symptoms like movement and daily living tasks. Participants take a daily tablet for up to 3 years, and researcher…

This study looks at the long-term safety of a drug called litifilimab for people with active lupus. About 864 adults who already completed a previous study will continue taking the drug for up to 3 years, along with their usual medications. Researchers will track side effects and…

This study tests a new drug called litifilimab for people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 548 adults already on standard lupus treatments will receive either litifilimab or a placebo as a shot every 4 weeks for a year. The goal …

This study tests an experimental drug called BIIB017 in children aged 10 to 17 with relapsing-remitting multiple sclerosis (MS). The goal is to see if the drug can reduce the number of MS attacks (relapses) and is safe for long-term use. Participants will receive either BIIB017 o…

This study looks at the long-term safety of the drug litifilimab for adults with a type of lupus that affects the skin (cutaneous lupus). Participants have already completed a previous study and did not get relief from standard antimalarial drugs. They will receive injections of …

This study looks at the long-term safety of a higher dose of nusinersen for people with spinal muscular atrophy (SMA). It includes 115 participants who already completed a previous nusinersen study. They will receive the drug every 4 months for up to 64 months, and researchers wi…

This study tests a new drug called litifilimab for people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 562 adults already on standard lupus treatments will receive either high-dose, low-dose litifilimab, or a placebo as injections every 4 we…

This study tests an experimental drug called tofersen in adults who carry a gene mutation (SOD1) that puts them at high risk for ALS, a severe nerve disease. Participants do not have ALS symptoms yet. The goal is to see if tofersen can delay or prevent the disease from appearing.…

This study looks at the long-term safety and effects of a drug called felzartamab in people who have had a kidney transplant and later developed antibody-mediated rejection (AMR). AMR occurs when the body's immune system attacks the new kidney. Participants who completed an earli…

This study looks at how many people with multiple sclerosis (MS) develop antibodies against the drug natalizumab when they receive it as an injection under the skin. Researchers will track about 400 patients from European MS registries, including both those new to the drug and th…

This study is a registry that collects information on up to 600 children in China who have spinal muscular atrophy (SMA). The goal is to learn how the disease progresses and how current treatments are used in real-world settings. No new treatment is given; the study simply observ…

This study uses data from large MS registries to monitor the long-term safety of Vumerity and Tecfidera in about 10,500 people with multiple sclerosis. Researchers will compare serious side effects like infections and cancer among those taking these drugs versus other MS treatmen…